Azur Pharma, Inc.

Receive alerts:
by e-mail
E-mail Your information will be added to a database with the sole purpose of serving your subscription. This database is the exclusive property of vLex Networks S.L. and will never be shared with any other company. By sending your request you accept the Data Protection Policy of vLex Networks S.L. I have read and accept the Terms of Use
via RSS

58 documents for Azur Pharma, Inc.

- Barr to Challenge Irish Drug Maker's Patent ; Seeks Fda's Ok for Generic Fazaclo
Montvale-based Barr Pharmaceuticals, Inc. on Monday said its subsidiary, Barr Laboratories Inc., is challenging an Irish company's patent for the schizophrenia drug FazaClo. Azur Pharma Ltd. of Ireland and partner company Cima Labs Inc. filed suit in federal court in Wilmington, Del., last week to block Barr from selling a generic version of FazaClo.
- The Record, Bergen County, NJ
- August 26, 2008
- Granting of Request for Early Termination of the Waiting Period Under the Premerger Notification Rules
...The listing for each transaction includes the transaction number and the parties to the tran... G Par Pharmaceutical Companies,. ... LP; Azur Pharma Public. ...
- Federal Register Nbr. 76 FR 77534, December 13, 2011
- Notices
- Federal Trade Commission
- AVANIR Announces Fiscal 2007 Fourth Quarter and Fiscal Year Financial Results.
...ALISO VIEJO, Calif. -- AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported unaudited financial r... fourth quarter of fiscal 2007 net profit includes income from discontinued operations of approximate... the previously announced sale of FazaClo to Azur Pharma Inc. and received an upfront payment of $42...
- Business Wire
- December 11, 2007

- TEVA PHARMACEUTICALS INDUSTRIES LTD. V. ASTRAZENECA PHARMACEUTICALS LP, (2011)
... PHARMACEUTICALS LP AND IPR PHARMACEUTICALS INC.,. Defendants-Appellees. 2011-1091. Appeal from th... same standard used by the District Court." Azur v. Chase Bank, USA, Nat'l Ass'n, 601 F.3d 212, 216...
- United States Court of Appeals for the Federal Circuit
- AVANIR Reports Third Quarter Fiscal 2007 Financial Results.
...ALISO VIEJO, Calif. -- AVANIR Pharmaceuticals (NASDAQ:AVNR) today reported financial results for... in the third quarter of fiscal 2007 included FazaClo[R] net revenues of $4.9 million. Gross mar... sale of FazaClo[R] (clozapine, USP) to Azur Pharma Inc. and received an upfront payment of $42...
- Business Wire
- August 08, 2007
- Antares Pharma Reports Fourth Quarter and Year End 2008 Financial and Operating Results.
EWING, N.J. -- Antares Pharma, Inc. (NYSE Amex: AIS) today reported financial and ope...related to an agreement with AZUR Pharma for the marketing of Elestrin; . * Announce...
- Business Wire
- March 25, 2009
- Antares Pharma Receives Milestone Payment and Additional Patent Related to Elestrin[R].
EWING, N.J. -- Antares Pharma, Inc. (AMEX:AIS) announced that the company received a ...(NASDAQ:BPAX) related to an agreement with AZUR Pharma for the marketing of Elestrin (estradiol ge...
- Business Wire
- January 06, 2009
- BioSante Pharmaceuticals Reports Receipt of $2.16 Million in Elestrin[TM] Royalty Buydown, and Financial Results for 2009.
...-- BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced the successful commpletion of the Azur Pharma Elestrin royalty buydown, and financial res...
- Business Wire
- March 30, 2010
- Antares Pharma Reports First Quarter 2009 Financial and Operating Results.
Total revenue increased to $2.0 million in Q1 2009 from $1.1 million in Q1... gel) was re-launched in the United States by Azur Pharma in April. . "As our products are patient fo...
- Business Wire
- May 13, 2009
- Elan Reports Fourth Quarter and Full-Year 2010 Financial Results.
... by 5% to $1.2 billion, led by an 18% increase in revenues from Tysabri. Our revenue increase com... divested its Prialt assets and rights to Azur Pharma International Limited (Azur) on May 5, 2010...
- Business Wire
- February 08, 2011